Pancreatic Ductal Adenocarcinoma (PDAC) Market Outlook

Thelansis’s “Pancreatic Ductal Adenocarcinoma (PDAC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pancreatic Ductal Adenocarcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pancreatic Ductal Adenocarcinoma (PDAC) Overview

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy arising from the exocrine epithelium of the pancreatic ducts, representing the vast majority of pancreatic cancers and carrying one of the poorest prognoses across all solid tumours. Its pathobiology is driven by a stepwise accumulation of somatic mutations — most critically activating KRAS mutations present in over 90% of cases — alongside inactivation of tumour suppressor genes including CDKN2A, TP53, and SMAD4, fostering unchecked cellular proliferation within a densely immunosuppressive, desmoplastic stroma that impedes drug delivery and immune surveillance. Clinically, PDAC is notoriously insidious; early disease is largely asymptomatic, with patients typically presenting at advanced stages with painless obstructive jaundice, profound unintentional weight loss, new-onset or worsening diabetes, epigastric pain radiating to the back, and cancer-associated thrombosis. Diagnostic workup incorporates contrast-enhanced CT for staging and resectability assessment, supplemented by endoscopic ultrasound-guided biopsy for tissue confirmation, while CA 19-9 serves as a clinically useful — though non-specific — serum tumour marker for monitoring. Surgical resection via pancreaticoduodenectomy remains the only potentially curative option, yet fewer than 20% of patients present with resectable disease; adjuvant chemotherapy with mFOLFIRINOX or gemcitabine-capecitabine is standard following resection. For locally advanced or metastatic disease, systemic chemotherapy with FOLFIRINOX or gemcitabine-nab-paclitaxel constitutes first-line palliation, with germline BRCA-mutated patients deriving benefit from PARP inhibitor maintenance therapy. Prognosis remains sobering, with five-year survival below 15% overall; optimal management demands early palliative care integration, nutritional support, pain management, and compassionate shared decision-making centred on preserving dignity and quality of life throughout the disease trajectory.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)